Joseph Errico
Psychiatry · Temecula, CANPI 1225085731
Payments from drug & device makers
Across 123 payments — averaging $3879.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$473K
- Otsuka America Pharmaceutical, Inc.$887
- Neurocrine Biosciences, Inc.$623
- Johnson & Johnson$576
- Teva Pharmaceuticals USA, Inc.$571
- E.r. Squibb & Sons, L.L.C.$405
- plus $1K from 5 others
What the payments were for
- Royalty or licence$472,71499%
- Food & beverage$4,4351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 25 | $472,714 |
| Otsuka America Pharmaceutical, Inc. | 34 | $887 |
| Neurocrine Biosciences, Inc. | 9 | $623 |
| Johnson & Johnson | 14 | $576 |
| Teva Pharmaceuticals USA, Inc. | 13 | $571 |
| E.r. Squibb & Sons, L.L.C. | 8 | $405 |
| AbbVie | 5 | $299 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $288 |
| Axsome Therapeutics, Inc. | 4 | $270 |
| Sunovion Pharmaceuticals Inc. | 4 | $259 |
| Alkermes, Inc. | 3 | $257 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIA$275,777
- XIA 3$196,937
- INGREZZA$509
- ARISTADA$493
- LYBALVI$467
- INVEGA SUSTENNA$356
- COBENFY$262
- CAPLYTA$250
- VRAYLAR$243
- LATUDA$242
- REXULTI$241
- Auvelity$228
- INVEGA TRINZA$211
- AUSTEDO$125
- ABILIFY MAINTENA$125
- Austedo XR$125
- ARISTADA INITIO$123
How this compares
$477,149 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 16 | $93,214 |
| Abilify MaintenaAripiprazole | 22 | $56,469 |
| RexultiBrexpiprazole | 21 | $30,616 |
| Invega SustennaPaliperidone Palmitate | 16 | $29,803 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 12 | $2,613 |
| Quetiapine Fumarate | 121 | $1,932 |
| Paliperidone ErPaliperidone | 14 | $1,398 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 51 | $1,189 |
| Trazodone Hcl | 163 | $976 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 60 | $891 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $869 |
| Fluvoxamine Maleate | 11 | $780 |
| Mirtazapine | 37 | $678 |
| Duloxetine Hcl | 68 | $677 |
| Olanzapine | 12 | $575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $571 | $93,21416 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $887 | $87,08543 claims |
| Johnson & JohnsonInvega Sustenna | $576 | $29,80316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Temecula
- Sana Johnson-QuijadaTemecula$2.5M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.